Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials
New supply agreement includes additional lots of intermediate drug product to support the manufacture of the rhenium (186Re) obisbemeda radiotherapeutic
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced an expansion of its collaboration with Piramal Pharma Solutions (PPS) to produce additional cGMP liposome intermediate drug product to meet the increase in demand for its lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, for ongoing and planned clinical trials.
The new supply agreement builds on the Master Services Agreement which the Company and PPS entered into in 2021 for the development, manufacture and supply of rhenium (186Re) obisbemeda.
“We significantly grew our clinical trial programs for central nervous system cancers in 2022 and we expect to continue this momentum into 2023,” said Marc H. Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. “Our strategic partnership with PPS will support our robust supply chain and manufacturing processes to keep ahead of our planned clinical development expansion and lay the groundwork for commercialization in the future.”
“The expansion of our collaboration with Plus Therapeutics validates the breadth and scale of our capabilities as a leading CDMO,” said Peter DeYoung, Chief Executive Officer of Piramal Pharma Solutions. “Our services allow us to deliver solutions that benefit our partners and ultimately patients.”
About Rhenium (186Re) Obisbemeda
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in CNS tumors in a safe, effective and convenient manner to optimize patient outcomes. Rhenium (186Re) obisbemeda has the potential to reduce risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue and gamma energy for live imaging.
About Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a contract development and manufacturing organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug product. PPS also offers development and manufacturing services for biologics including vaccines, gene therapies made possible through Piramal Pharma Limited’s investment in Yapan Bio Private Limited.
For more information visit: www.piramalpharmasolutions.com | LinkedIn| Facebook | Twitter
About Piramal Pharma Limited
Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL’s associate companies, Allergan India Private Limited is a JV with AbbVie Inc. and has emerged as one of the market leaders in the ophthalmology therapy area. Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information visit: www.piramal.com/pharma | LinkedIn | Facebook | Twitter.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas.
For more information, visit https://plustherapeutics.com/
Source: Plus Therapeutics
FC Global Strategies enables medical, pharma, healthcare, medical device and healthcare IT companies to achieve their business and financial goals
Since 1979 FC Global Strategies has enabled companies globally to achieve their business and financial objectives.
If your company has business or financial objectives check out:
Strategic advisory services provided by FC Global Strategies
Medical and Pharma Insider’s AI Connect Marketing Program
Click here to schedule a complimentary call to discuss your company's business and financial goals.
Medical and Pharma Insider is a program of FC Global Strategies.
FC Global Strategies' Contacts
North America and Latin America
Jeffrey Friedland, +1 646 450 8909
The Middle East, North Africa and Eastern Europe
David Krutonog, +972 50 974 3429
Southeast Asia, Asia-Pacific, Australia, and New Zealand
Ross Swan, +65 9181 9472